Building new cardiac vasculature and myocardium: where are we at?
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F21%3A00123962" target="_blank" >RIV/00216224:14110/21:00123962 - isvavai.cz</a>
Result on the web
<a href="https://journals.lww.com/co-cardiology/Abstract/2021/11000/Building_new_cardiac_vasculature_and_myocardium_.9.aspx" target="_blank" >https://journals.lww.com/co-cardiology/Abstract/2021/11000/Building_new_cardiac_vasculature_and_myocardium_.9.aspx</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1097/HCO.0000000000000905" target="_blank" >10.1097/HCO.0000000000000905</a>
Alternative languages
Result language
angličtina
Original language name
Building new cardiac vasculature and myocardium: where are we at?
Original language description
Purpose of review This review describes the latest advances in cell therapy, biomaterials and 3D bioprinting for the treatment of cardiovascular disease. Recent findings Cell therapies offer the greatest benefit for patients suffering from chronic ischemic and nonischemic cardiomyopathy. Rather than replacing lost cardiomyocytes, the effects of most cell therapies are mediated by paracrine signalling, mainly through the induction of angiogenesis and immunomodulation. Cell preconditioning, or genetic modifications are being studied to improve the outcomes. Biomaterials offer stand-alone benefits such as bioactive cues for cell survival, proliferation and differentiation, induction of vascularization or prevention of further cardiomyocyte death. They also provide mechanical support or electroconductivity, and can be used to deliver cells, growth factors or drugs to the injured site. Apart from classical biomaterial manufacturing techniques, 3D bioprinting offers greater spatial control over biomaterial deposition and higher resolution of the details, including hollow vessel-like structures. Cell therapy induces mainly angiogenesis and immunomodulation. The ability to induce direct cardiomyocyte regeneration to replace the lost cardiomyocytes is, however, still missing until embryonic or induced pluripotent stem cell use becomes available. Cell therapy would benefit from combinatorial use with biomaterials, as these can prolong cell retention and survival, offer additional mechanical support and provide inherent bioactive cues. Biomaterials can also be used to deliver growth factors, drugs, and other molecules. 3D bioprinting is a high-resolution technique that has great potential in cardiac therapy.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Current opinion in cardiology
ISSN
0268-4705
e-ISSN
1531-7080
Volume of the periodical
36
Issue of the periodical within the volume
6
Country of publishing house
US - UNITED STATES
Number of pages
7
Pages from-to
728-734
UT code for WoS article
000703608800009
EID of the result in the Scopus database
2-s2.0-85118283634